Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Erik Astrup Dahm

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Medical Sciences (Basel, Switzerland)|July 2, 2021
Cancer and Thrombosis: New Treatments, New ChallengesAnders Erik Astrup Dahm
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 24, 2023
[Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital]Torstein Storlien, Anders Erik Astrup Dahm
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 16, 2002
[Phenytoin poisoning caused by interaction with ticlopidine]Anders Erik Astrup Dahm, Odd Brørs
Research and Practice in Thrombosis and Haemostasis|May 20, 2021
Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysisChristopher Friis Berntsen, Pernille Rootwelt, Anders Erik Astrup Dahm
Thrombosis and Haemostasis|October 10, 2023
Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous ThromboembolismParwana Hussaini, Trine-Lise Larsen, Waleed Ghanima, et al.
British Journal of Haematology|May 14, 2011
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphismAstrid Bergrem, Anders Erik Astrup Dahm, Anne Flem Jacobsen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 19, 2023
[Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients]Trine-Lise Larsen, Waleed Ghanima, Per Morten Sandset, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2021
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitorDeeksha Khialani, Sowmya Vasan, Mary Cushman, et al.
Journal of Medical Case Reports|April 25, 2018
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case reportAndreas Hanssønn Habberstad, Hoa Thi Tuyet Tran, Ulla Randen, et al.
Thrombosis Research|July 23, 2017
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7Xue Yan Cui, Grethe Skretting, Mari Tinholt, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Medical Sciences (Basel, Switzerland)|July 2, 2021
Cancer and Thrombosis: New Treatments, New ChallengesAnders Erik Astrup Dahm
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 24, 2023
[Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital]Torstein Storlien, Anders Erik Astrup Dahm
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 16, 2002
[Phenytoin poisoning caused by interaction with ticlopidine]Anders Erik Astrup Dahm, Odd Brørs
Research and Practice in Thrombosis and Haemostasis|May 20, 2021
Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysisChristopher Friis Berntsen, Pernille Rootwelt, Anders Erik Astrup Dahm
Thrombosis and Haemostasis|October 10, 2023
Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous ThromboembolismParwana Hussaini, Trine-Lise Larsen, Waleed Ghanima, et al.
British Journal of Haematology|May 14, 2011
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphismAstrid Bergrem, Anders Erik Astrup Dahm, Anne Flem Jacobsen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 19, 2023
[Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients]Trine-Lise Larsen, Waleed Ghanima, Per Morten Sandset, et al.
Journal of Thrombosis and Haemostasis : JTH|March 28, 2021
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitorDeeksha Khialani, Sowmya Vasan, Mary Cushman, et al.
Journal of Medical Case Reports|April 25, 2018
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case reportAndreas Hanssønn Habberstad, Hoa Thi Tuyet Tran, Ulla Randen, et al.
Thrombosis Research|July 23, 2017
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7Xue Yan Cui, Grethe Skretting, Mari Tinholt, et al.
Pageof 2